Leukemia Drug-Free remission: new study tests tapering strategy
NCT ID NCT05753384
First seen May 04, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This study tests whether slowly reducing the dose of tyrosine kinase inhibitor (TKI) medication over 12 months helps more chronic myeloid leukemia (CML) patients stop treatment entirely without the cancer returning. About 170 adults with stable CML will be randomly assigned to either stop their TKI suddenly or taper the dose by half for a year before stopping. The goal is to see if more patients can stay in remission without daily pills, improving quality of life and reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Brive la Gaillarde
Brive-la-Gaillarde, France
-
CH Versailles
Versailles, France
-
CHI Creteil
Créteil, France
-
CHU Limoges
Limoges, France
-
Centre Léon Bérard
Lyon, France
-
Ch Annecy
Annecy, France
-
Ch Bayonne
Bayonne, France
-
Ch Chambery
Chambéry, France
-
Ch La Rochelle
La Rochelle, France
-
Ch Mont de Marsan
Mont-de-Marsan, France
-
Ch Perigueux
Périgueux, France
-
Chu Angers
Angers, France
-
Chu Brest
Brest, France
-
Chu Lille
Lille, France
-
Chu Nancy
Nancy, France
-
Chu Nantes
Nantes, France
-
Chu Poitiers
Poitiers, France
-
Chu Tours
Tours, France
-
Hopital Prive Du Confluent
Nantes, France
-
Oncopole Toulouse
Toulouse, France
Conditions
Explore the condition pages connected to this study.